Ataraxis AI launched Ataraxis ARC, a large prospective study evaluating how clinical AI helps build truly personalized treatment plans and impacts outcomes for real patients.
Public source
Publisher name
Public post
Clinical AI is only as good as the outcomes it drives! At Ataraxis, we're not just building AI models - we're proving they change treatment decisions and improve patient…
Company
Ataraxis AI
Transforming Cancer Care with AI Precision Medicine
- Industry
- Artificial Intelligence
- Location
- New York, US
- Company size
- 11–50 employees
About Ataraxis AI
Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai.
See moreLatest activity
Latest activity from Ataraxis AI
7 signals
Research & Knowledge
Ataraxis AI is launching Ataraxis ARC, a prospective study designed to evaluate AI model predictions and link them with real-world cancer patient outcomes, with initial enrollment of 1,000 patients across top cancer centers.
Research & Knowledge
Ataraxis AI is launching Ataraxis ARC, a prospective study designed to evaluate AI model predictions and link them with real-world cancer patient outcomes, with initial enrollment of 1,000 patients across top cancer centers.
Research & Knowledge
Ataraxis AI is launching a prospective registry study evaluating its AI prediction in more than just breast cancer.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Association of Cancer Care Centers
Association of Cancer Care Centers is launching an AI in Precision Oncology call for submissions to explore the responsible, evidence-based application of AI in cancer care.
Research & Knowledge
Cure51
Cure51 published a Rosalind Study combining multiple layers of patient data, including genomics, transcriptomics, pathology, clinical history, and multi-omics insights, to integrate complex datasets and identify patterns for AI-driven treatment prediction.
Research & Knowledge
Elephas
Elephas introduced an AI Avatar that quickly walks through the ASCO2026 poster showing 93% concordance between a cancer patient's clinical response on immunotherapy and the Functional Precision Medicine platform's predicted response.
Research & Knowledge
Mango Sciences
Mango Sciences published a blog exploring how AI is making a difference in patient care, including detecting breast cancers, reducing documentation time, and identifying potential clinical trial patients in oncology.
Research & Knowledge
ArteraAI